Blueprint Medicines Yönetim

Yönetim kriter kontrolleri 2/4

Blueprint Medicines CEO'su Kate Haviland, Apr2022 tarihinde atandı, in görev süresi 2.58 yıldır. in toplam yıllık tazminatı $ 6.43M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.2% maaş ve 87.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.094% ine doğrudan sahiptir ve bu hisseler € 5.37M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.2 yıl ve 9.5 yıldır.

Anahtar bilgiler

Kate Haviland

İcra Kurulu Başkanı

US$6.4m

Toplam tazminat

CEO maaş yüzdesi	12.2%
CEO görev süresi	2.6yrs
CEO sahipliği	0.09%
Yönetim ortalama görev süresi	4.2yrs
Yönetim Kurulu ortalama görev süresi	9.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Kate Haviland'un ücretlendirmesi Blueprint Medicines'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$128m
Jun 30 2024	n/a	n/a	-US$205m
Mar 31 2024	n/a	n/a	-US$288m
Dec 31 2023	US$6m	US$782k	-US$507m
Sep 30 2023	n/a	n/a	-US$555m
Jun 30 2023	n/a	n/a	-US$554m
Mar 31 2023	n/a	n/a	-US$581m
Dec 31 2022	US$6m	US$701k	-US$558m
Sep 30 2022	n/a	n/a	-US$718m
Jun 30 2022	n/a	n/a	-US$702m
Mar 31 2022	n/a	n/a	-US$650m
Dec 31 2021	US$4m	US$501k	-US$644m
Sep 30 2021	n/a	n/a	-US$411m
Jun 30 2021	n/a	n/a	US$340m
Mar 31 2021	n/a	n/a	US$325m
Dec 31 2020	US$2m	US$461k	US$314m
Sep 30 2020	n/a	n/a	US$333m
Jun 30 2020	n/a	n/a	-US$395m
Mar 31 2020	n/a	n/a	-US$371m
Dec 31 2019	US$3m	US$432k	-US$348m
Sep 30 2019	n/a	n/a	-US$362m
Jun 30 2019	n/a	n/a	-US$340m
Mar 31 2019	n/a	n/a	-US$267m
Dec 31 2018	US$3m	US$393k	-US$237m
Sep 30 2018	n/a	n/a	-US$205m
Jun 30 2018	n/a	n/a	-US$170m
Mar 31 2018	n/a	n/a	-US$177m
Dec 31 2017	US$1m	US$353k	-US$148m

Tazminat ve Piyasa: Kate 'nin toplam tazminatı ($USD 6.43M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.61M ).

Tazminat ve Kazançlar: Kate şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Kate Haviland (48 yo)

2.6yrs

Görev süresi

US$6,432,012

Tazminat

Ms. Kathryn Haviland, also known as Kate, M.B.A, is Independent Director of Bicara Therapeutic, Inc. from September 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serv...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kathryn Haviland	President	2.6yrs	US$6.43m	0.094% € 5.4m
Alexis Borisy	Co-Founder & Director	no data	US$397.33k	0.11% € 6.4m
Michael Landsittel	Chief Financial Officer	8.8yrs	US$2.19m	0.056% € 3.2m
Christina Rossi	Chief Operating Officer	2.6yrs	US$2.81m	0.043% € 2.4m
Percy Carter	Chief Scientific Officer	3.5yrs	US$2.30m	0.078% € 4.4m
Fouad Namouni	President of Research & Development	4.2yrs	US$2.80m	0.050% € 2.9m
Ariel Hurley	Senior VP	1.8yrs	Veri yok	0.023% € 1.3m
Jenna Cohen	Senior Director & Head of Investor Relations	no data	Veri yok	Veri yok
Tracey McCain	Executive VP	8.2yrs	US$2.34m	0.046% € 2.6m
Debra Durso-Bumpus	Chief People Officer	4.8yrs	Veri yok	0.019% € 1.1m
Julian Baker	Senior Vice President of Corporate Affairs	no data	Veri yok	Veri yok
Becker Hewes	Chief Medical Officer	4.5yrs	Veri yok	0.046% € 2.6m

4.2yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: 2L9 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kathryn Haviland	President	2.6yrs	US$6.43m	0.094% € 5.4m
Alexis Borisy	Co-Founder & Director	13.6yrs	US$397.33k	0.11% € 6.4m
George Demetri	Chair of Scientific Advisory Board	12.5yrs	US$333.38k	Veri yok
Lynn Seely	Lead Independent Director	8.6yrs	US$452.33k	0.017% € 986.4k
Charles Sawyers	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Brian Druker	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Nicholas Lydon	Member of Scientific Advisory Board & Independent Director	13.6yrs	US$417.33k	0.088% € 5.0m
Lonnel Coats	Independent Director	8.8yrs	US$419.33k	0% € 0
William Hahn	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Scott Lowe	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Daniella Beckman	Independent Director	2.9yrs	US$422.33k	0.014% € 770.7k
Jeffrey Albers	Chairman	10.3yrs	US$526.08k	0.24% € 13.9m

9.5yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2L9 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.5 yıldır).

Blueprint Medicines Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Scientific Officer recently sold €387k worth of stock

Blueprint Medicines Corporation, Annual General Meeting, Jun 12, 2024

President recently sold €1.0m worth of stock

Chief Scientific Officer recently sold €112k worth of stock

Insider recently sold €72k worth of stock

Blueprint Medicines Corporation Announces Board Changes

Recent updates

Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024

Third quarter 2024 earnings released: US$0.89 loss per share (vs US$2.20 loss in 3Q 2023)

Forecast to breakeven in 2026

Blueprint Medicines Corporation to Report Q3, 2024 Results on Oct 30, 2024

No longer forecast to breakeven

Blueprint Medicines Corporation Raises Revenue Guidance for the Full Year 2024

Forecast to breakeven in 2026

Blueprint Medicines Corporation to Report Q2, 2024 Results on Aug 01, 2024

Chief Scientific Officer recently sold €387k worth of stock

Blueprint Medicines Corporation to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting

Forecast to breakeven in 2026

Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$1.45 (vs US$2.16 loss in 1Q 2023)

Blueprint Medicines Corporation, Annual General Meeting, Jun 12, 2024

Blueprint Medicines Corporation to Report Q1, 2024 Results on May 02, 2024

President recently sold €1.0m worth of stock

Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$8.37 loss per share (vs US$9.35 loss in FY 2022)

Forecast to breakeven in 2026

Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year 2024

Blueprint Medicines Corporation to Report Q4, 2023 Results on Feb 15, 2024

Blueprint Medicines' Ayvakyt (Avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis

Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted At 2023 Ash Annual Meeting

Blueprint Medicines' Ayvakyt (Avapritinib) Receives Positive Chmp Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis

New major risk - Share price stability

Third quarter 2023 earnings released: US$2.20 loss per share (vs US$2.23 loss in 3Q 2022)

Blueprint Medicines Corporation to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: US$2.19 loss per share (vs US$2.68 loss in 2Q 2022)

Chief Scientific Officer recently sold €112k worth of stock

Blueprint Medicines Announces Clinical Data for Multiple Programs Across its Precision Therapy Portfolio at the 2023 American Society of Clinical Oncology

Blueprint Medicines Corporation Announces NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT (avapritinib) in Patients with Indolent Systemic Mastocytosis

Blueprint Medicines Corporation Announces U.S. Food and Drug Administration Approves AYVAKIT(R) (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

Blueprint Medicines Corporation Provides Revenue Guidance for the Year 2023

First quarter 2023 earnings released: US$2.16 loss per share (vs US$1.79 loss in 1Q 2022)

Insider recently sold €72k worth of stock

Full year 2022 earnings released: US$9.35 loss per share (vs US$11.01 loss in FY 2021)

Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year of 2023

Blueprint Medicines Corporation Announces Partial Clinical Hold for Phase 1/2 Vela Trial of Blu-222

Blueprint Medicines Corporation to Report Q4, 2022 Results on Feb 16, 2023

Blueprint Medicines Corporation Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT(R)

Blueprint Medicines Corporation Announces Board Changes

Blueprint Medicines Corporation Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis

Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (Avapritinib) for the Treatment of Indolent Systemic Mastocytosis

Third quarter 2022 earnings released: US$2.23 loss per share (vs US$2.00 loss in 3Q 2021)

Blueprint Medicines Corporation Provides Revenue Guidance for 2022

President of Research & Development recently sold €235k worth of stock

Blueprint Medicines Corporation Announces CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis

Blueprint Medicines Announces Positive Top-Line Results from Pioneer Trial of AYVAKIT® (Avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints

Insider recently sold €309k worth of stock

Second quarter 2022 earnings released: US$2.68 loss per share (vs US$1.86 loss in 2Q 2021)

Blueprint Medicines Corporation Provides Revenue Guidance for 2022

Blueprint Medicines Corporation announced that it expects to receive $400 million in funding from Sixth Street Partners

Blueprint Medicines Appoints Habib Dable to its Board of Directors

Chief Scientific Officer recently sold €107k worth of stock

Insufficient new directors

Blueprint Medicines Corporation Provides Revenue Guidance for the Year 2022

Blueprint Medicines Corporation, Annual General Meeting, Jun 21, 2022

Blueprint Medicines Corporation Announces Blu-945 Proof-Of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in Egfr-Mutant Non-Small Cell Lung Cancer

Blueprint Medicines Corporation and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Blueprint Medicines Corporation Provides Earnings Guidance for 2022

Blueprint Medicines Corporation to Report Q4, 2021 Results on Feb 16, 2022

Blueprint Medicines Corporation's AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis

Blueprint Medicines Corporation (NasdaqGS:BPMC) completed the acquisition of Lengo Therapeutics, Inc.

Blueprint Medicines Corporation Publishes Results from Two Registration Studies of Ayvakit® (Avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis

Insufficient new directors

Blueprint Medicines Corporation (NasdaqGS : BPMC) agreed to acquire Lengo Therapeutics, Inc. for $470 million.

President of Research & Development recently sold €274k worth of stock